Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced Melanoma

19 Dec 2018

Abstract excerpt

AIM: The cost-effectiveness of treatment sequences in BRAF-mutant advanced melanoma. MATERIALS & METHODS: A discrete event simulation model was developed to estimate total costs and health outcomes over a patient's lifetime (30 years). Efficacy was based on the CheckMate 067/069 trials and a matching-adjusted-indirect comparison between immuno-oncology and targeted therapies. Safety, cost (in US dollars; US...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cutaneous Melanoma Detection and Management
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30563395
DOI: 10.2217/imt-2018-0168

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced MelanomaPMID 30563395Read ↗

Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.Semantic proximity Read ↗

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.Semantic proximity Read ↗

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Cost-Effectiveness of Immune Checkpoint Inhibition and Targeted Treatment in Combination as Adjuvant Treatment of Patient with BRAF-Mutant Advanced MelanomaSemantic proximity Read ↗

Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy.Semantic proximity Read ↗

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.Semantic proximity Read ↗

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.Semantic proximity Read ↗

Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.Semantic proximity Read ↗

First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis.Semantic proximity Read ↗

Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.Semantic proximity Read ↗

Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective.Semantic proximity Read ↗

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.